![]() | Only 14 pages are availabe for public view |
Abstract The 1eukocyte adherence inhibition (LAX) test was app1ied to detect ce11-mediated immunoreactivity re1ated to human urinary b1adder carcinoma. Pre1iminary resu1ts - .. •· showed nonspecific toxic effect of high ca1f serum (CS) concentrations, thus CS was e1iminated from incubation medium. Fo11owing incubation of periphera1 b1ood 1eukocytes (PBL) from contro1 subjects in protein-free medium, or medium containing extracts from either urinary b1adder transitiona1 ce11 carcinoma (TCC) or squamous ce11 carcinoma (SqCC) 1 percentage adherent ce11s was estimated and considered as contro1 1eve1 of adherence. A1though tumor extracts were prepared.by one and the same method, different tumor-antigen preparations varied vast1y in their abi1ity to give specific adherence inhibition. Some preparations (SqCC 1 1 TCC 1 and TCC 2) consistent1y gave a high tumor-specific LAX (20~ decreased adherence), whi1 another preparation (SqCC 2) did not. Therefor extracts must be screened for activity in the LAX test before being used for investigating ce11- mediated immunity (CMX) of cancer patients. Since the previous extracts were not enough, adequate vo1umes were prepared from urinary b1adder squamous ce11 carcinoma (SqCC 3) 1 transitiona1 ce11 carcinoma (TCC 3) 1 adenocarcinoma (AdC) and poo1ed contro1 PBL 68 (HL-A). AdC and HL-A (histocompatibi1ity) were used as contro1 antigens. The nontoxic concentration of extracts was found to be ~ 150 pg/m1 in case of SqCC 3 1 TCC 3 and ~ -- A~C and ~ 250 ~g/m1 in case of HL-A extracts. PBL from ~ out of ~ TCC patients showed specific LAI when reacted with TCC 3 extract, whi1 no reactivity was observed when they were reacted with SqCC 3 1 AdC and HL-A extracts. This specific reactivity indicates the pr~sence of tissue-type specific antigen’s’ (TTSA) in TCC 3 extract. Simi1ar resu1ts were obtained when PBL from 6 out of 6 SqCC patients reacted specifica11y with SqCC 3 extract but not with TCC 3 1 AdC and HL-A extracts. Thus SqCC 3 extraet is characterised by the presence of TTSA. No cross-reactivity was observed between the two types of urinary b1adder carcinoma. This indicates antigenic differences between these two tumor types of the same site but of different ce11 types. LAI responce was confirmed to be stage-dependent phenomenon. PBL from 7 out of8 SqCC patients (stage 11 ·or III disease) showed specific reactivity with SqCC 3 antigenic extract and non with TCC 3 1 AdC and HL-A extracts. On the other hand on1y 1 out of 13 PBL samp1es derived from sqec patients (stage IV) showed specific reactivity with SqCC 3 reactive antigenic extract. LAI was thus high in patients carrying ear1y-stage neop1asm~ut not with large tumor burden. Within one month of surgical removal of stage II ’ or III SqCC, 10 out of 10 SqCC pa~ients showed sp~cific - - reactivity with SqCC 3 antigenic extract. Thus specific LAI was still retained by patients’ PBL. It seems thus that the use of the LAI test in monitoring patients with urinary bladder carcinoma is warranted. |